Teva Hopes For Revenue Growth For First Time Since 2017
Executive Summary
The company’s new CEO Richard Francis is aiming for revenue growth this year; it would be the first time since 2017.
You may also be interested in...
Teva Returns To Growth For First Time In Six Years
The company also announced plans to divest its active pharmaceutical ingredients (API) business as part of its ‘Pivot to Growth’ strategy.
Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.
Teva Clears Another Overhang With US Price-Fixing Settlement
The settlement closes a multi-year investigation by the US Department of Justice into generic drug price fixing schemes that involved charges against seven companies.